Dyadic International (NASDAQ:DYAI) Stock Passes Below Fifty Day Moving Average – Should You Sell?

Dyadic International Inc. (NASDAQ:DYAI) shares crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.93 and traded as low as $0.90. Dyadic International shares last traded at $0.90, with a volume of 21,630 shares.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on DYAI shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research report on Monday, December 29th. HC Wainwright initiated coverage on shares of Dyadic International in a research note on Thursday, October 23rd. They set a “buy” rating and a $3.00 target price for the company. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Dyadic International currently has an average rating of “Hold” and a consensus target price of $3.00.

Dyadic International Trading Down 1.3%

The firm has a market cap of $32.57 million, a P/E ratio of -3.75 and a beta of 1.26. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.85 and a current ratio of 2.85. The firm has a fifty day moving average of $0.93 and a 200-day moving average of $0.98.

Dyadic International (NASDAQ:DYAI) last issued its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Dyadic International had a negative return on equity of 537.31% and a negative net margin of 221.09%.The company had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.22 million. Equities research analysts forecast that Dyadic International Inc. will post -0.18 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Truist Financial Corp raised its holdings in shares of Dyadic International by 30.5% during the third quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after buying an additional 76,200 shares during the last quarter. Marathon Capital Management bought a new position in Dyadic International in the 3rd quarter worth approximately $41,000. Apis Capital Advisors LLC acquired a new stake in Dyadic International in the 3rd quarter valued at approximately $1,817,000. Bank of America Corp DE raised its stake in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 26,965 shares in the last quarter. Finally, AlphaCore Capital LLC bought a new stake in Dyadic International during the 2nd quarter valued at $50,000. Institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.